RedHill Biopharma postpones shareholder meeting over quorum

RedHill Biopharma Ltd. reports that its Annual General Meeting of Shareholders scheduled for August 6, 2026 was adjourned due to a lack of required legal quorum.

Rhea-AI Filing Summary

RedHill Biopharma Ltd. reports that its Annual General Meeting of Shareholders scheduled for August 6, 2026 was adjourned due to a lack of required legal quorum. Under its Amended and Restated Articles of Association, the meeting will reconvene on August 7, 2026 at 3:00 p.m. Israel time at the company’s Tel Aviv offices.

The report is also incorporated by reference into multiple existing registration statements on Forms S-8 and F-3, meaning the disclosed information is now legally part of those previously filed offerings documentation.

Key Figures

AGM original date: August 6, 2026 AGM reconvened date and time: August 7, 2026, at 3:00 p.m. Israel time Commission File Number: 001-35773

3 metrics

AGM original date August 6, 2026 Scheduled date of the Annual General Meeting of Shareholders before adjournment

AGM reconvened date and time August 7, 2026, at 3:00 p.m. Israel time Time the Annual General Meeting of Shareholders will reconvene at company offices

Commission File Number 001-35773 SEC commission file number for RedHill Biopharma Ltd.

Key Terms

Report of Foreign Private Issuer, Annual General Meeting of Shareholders, quorum, incorporated by reference, +2 more

6 terms

Report of Foreign Private Issuer regulatory

"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A report of a foreign private issuer is a formal filing that a non‑U.S. company makes to U.S. regulators to share important business, financial, or governance information with American investors. Think of it as a regular update or press packet that keeps investors informed about events that could change a company’s value—like earnings, management changes, contracts, or regulatory developments—so investors can make timely, informed decisions.

Annual General Meeting of Shareholders regulatory

"the adjournment of the Annual General Meeting of Shareholders scheduled"

quorum regulatory

"scheduled for August 6, 2026, due to a lack of required legal quorum"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

incorporated by reference regulatory

"This Form 6-K is hereby incorporated by reference into the Company's Registration"

Registration Statements on Form S-8 regulatory

"incorporated by reference into the Company's Registration Statements on Form S-8"

Registration Statements on Form F-3 regulatory

"and its Registration Statements on Form F-3 filed with the Securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RedHill Biopharma (RDHL) announce about its 2026 annual shareholder meeting?

RedHill Biopharma adjourned its Annual General Meeting scheduled for August 6, 2026 because a required legal quorum was not reached. The company plans to reconvene the meeting on August 7, 2026 at its offices in Tel Aviv.

Why was RedHill Biopharma's (RDHL) Annual General Meeting adjourned?

The meeting was adjourned because the company did not achieve the required legal quorum under its Amended and Restated Articles of Association. Without this quorum, shareholder resolutions cannot be voted on, so the meeting must be held at a later date.

When and where will RDHL's adjourned Annual General Meeting reconvene?

The adjourned Annual General Meeting will reconvene on August 7, 2026 at 3:00 p.m. Israel time at RedHill Biopharma’s offices at 21 Ha'arba’a Street, Tel Aviv. Shareholders may attend on that new date and time.

What is the significance of this RDHL report being incorporated by reference into its registration statements?

Incorporation by reference means the information in this report is now legally part of RedHill’s existing Forms S-8 and F-3. Investors relying on those registration statements must consider this report as included in the offering disclosures.

What type of SEC report did RedHill Biopharma (RDHL) file and for which period?

RedHill Biopharma filed a Form 6-K Report of Foreign Private Issuer for the month of August 2026. This form allows foreign private issuers to furnish current information to U.S. investors between annual reports.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 09:01 AM Accepted by SEC EDGAR 08/06/2026 - 09:00 AM Learn about SEC filing dates

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of August 2026

Commission File No.: 001-35773

REDHILL BIOPHARMA LTD.

(Translation of registrant’s name into English)

21 Ha'arba’a Street, Tel Aviv, 6473921, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F ☒        Form 40-F ☐

RedHill Biopharma Ltd. (the “Company”) announces today the adjournment of the Annual General Meeting of Shareholders scheduled for August 6, 2026, due to a lack of required legal quorum.

In accordance with the Company’s Amended and Restated Articles of Association, the Annual General Meeting of Shareholders will reconvene on August 7, 2026, at 3:00 p.m. Israel time at the Company’s office.

This Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327), on March 25, 2025 (File No. 333-286082) and on January 22, 2026 (File No. 333-292879), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, on August 9, 2024 (File No. 333-281417) and on July 2, 2026 (File No. 333-297223).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

	REDHILL BIOPHARMA LTD.
	(the “Registrant”)
Date: August 6, 2026	By:	/s/ Dror Ben-Asher
	Name:	Dror Ben-Asher
	Title:	Chief Executive Officer